What is Scientific Validity under EU IVDR 2017/746?

Scientific validity refers to the association between an in vitro diagnostic (IVD) device’s analyte and the clinical condition or physiological state it is intended to detect, measure, or predict. It establishes the clinical relevance of the analyte and ensures that the test has a sound scientific basis before it can be used in medical decision-making.

What are the key considerations for developing Scientific Validity under EU IVDR 2017/746?

Key considerations include: - Clearly defining the analyte and intended purpose of the device. - Establishing the clinical association between the analyte and the target condition. - Reviewing peer-reviewed literature, guidelines, and expert consensus. - Demonstrating consistency and reliability across different studies and populations. - Ensuring alignment with regulatory expectations and Annex XIII requirements.

What are the different sources of information for compiling Scientific Validity under EU IVDR 2017/746?

Scientific validity can be supported through multiple sources such as: - Published peer-reviewed scientific literature. - Clinical guidelines from recognized medical associations. - Authoritative textbooks and consensus papers. - Results from prior clinical performance studies. - Existing regulatory or scientific databases.

What is the step-by-step process for compiling Scientific Validity under EU IVDR 2017/746?

The process generally involves: - Define the analyte and intended clinical condition (as per device’s intended use). - Collect scientific evidence from peer-reviewed publications, clinical guidelines, and authoritative sources. - Assess the strength and relevance of evidence to ensure clinical association is valid. - Document gaps or limitations in available evidence and provide justification. - Summarize findings in the Scientific Validity Report (part of the Performance Evaluation Report). - Ensure ongoing updates as new evidence emerges during the device’s lifecycle.

Scientific Validity under EU IVDR 2017/746

Understanding Scientific Validity Under IVDR
The EU IVDR (Regulation 2017/746) sets strict rules to ensure that in-vitro diagnostic (IVD) devices are scientifically reliable and safe for patients. One of the core requirements is scientific validity, which means proving that the analyte being measured (such as a biomarker, substance, or signal) is truly linked to the medical condition the device claims to detect. Without this proof, the device cannot be CE-marked or marketed in the EU. Scientific validity must be supported by strong and traceable evidence. Manufacturers usually demonstrate this through systematic literature reviews, clinical guidelines, peer-reviewed research, or if needed proof-of-concept or clinical performance studies. This evidence must also reflect the current state of the art, meaning it should be aligned with the latest scientific standards and regularly updated as new data becomes available. All methods, data sources, and selection criteria must be clearly documented in the Performance Evaluation Plan (PEP) and performance evaluation report. Under the IVDR, scientific validity forms the first part of a broader performance evaluation, which also includes analytical performance (how accurately the device measures the analyte) and clinical performance (how well the results predict or support clinical diagnosis). Even low-risk Class A devices must maintain scientific validity documentation, while higher-risk devices (Classes B, C, D) require more comprehensive and robust evidence. This requirement applies not only to traditional IVDs but also to software used in diagnostics, calibrators, and control materials. Because IVDR demands transparent, up-to-date scientific justification, manufacturers must continuously monitor new research and update their technical files. This stricter process increases scientific rigor across the IVD industry and ensures that every test placed on the EU market is grounded in solid, verifiable scientific knowledge.

Understanding Scientific Validity Under IVDR

The EU IVDR (Regulation 2017/746) sets strict rules to ensure that in-vitro diagnostic (IVD) devices are scientifically reliable and safe for patients. One of the core requirements is scientific validity, which means proving that the analyte being measured (such as a biomarker, substance, or signal) is truly linked to the medical condition the device claims to detect. Without this proof, the device cannot be CE-marked or marketed in the EU.

Scientific validity must be supported by strong and traceable evidence. Manufacturers usually demonstrate this through systematic literature reviews, clinical guidelines, peer-reviewed research, or if needed proof-of-concept or clinical performance studies. This evidence must also reflect the current state of the art, meaning it should be aligned with the latest scientific standards and regularly updated as new data becomes available. All methods, data sources, and selection criteria must be clearly documented in the Performance Evaluation Plan (PEP) and performance evaluation report.

Under the IVDR, scientific validity forms the first part of a broader performance evaluation, which also includes analytical performance (how accurately the device measures the analyte) and clinical performance (how well the results predict or support clinical diagnosis). Even low-risk Class A devices must maintain scientific validity documentation, while higher-risk devices (Classes B, C, D) require more comprehensive and robust evidence. This requirement applies not only to traditional IVDs but also to software used in diagnostics, calibrators, and control materials.

Because IVDR demands transparent, up-to-date scientific justification, manufacturers must continuously monitor new research and update their technical files. This stricter process increases scientific rigor across the IVD industry and ensures that every test placed on the EU market is grounded in solid, verifiable scientific knowledge.

Introduction

Regulation (EU) 2017/746 of the European Union establishes strict requirements for IVD manufacturers, especially in terms of proving scientific validity with its emphasis on patient safety, IVDR ensures that devices are evaluated based on comprehensive, transparent, and harmonized evidence requirements. A core component of the IVDR is the concept of scientific validity, which manufacturers must establish for each in vitro diagnostic device to demonstrate its association with a medical condition or physiological state.

What is Scientific validity and its Purpose under EU IVDR 2017

Under the EU IVDR 2017/746 Article 56 and Annex XIII, scientific validity refers to the demonstration of an association between an analyte (the substance being measured) and a clinical condition or physiological state. This association is critical for ensuring the IVD device’s ability to contribute to diagnosis, monitoring, or prediction in the context of its intended use. The scientific validity in IVD devices must be based on robust and up-to-date scientific evidence from sources such as systematic literature reviews, clinical practice guidelines, and peer-reviewed studies. If this association is not established, the IVD may be rejected for CE-marking in the European market, significantly affecting its market access.

How Manufacturers Should Document Scientific Validity

Systematic Literature Review: Manufacturers must conduct thorough and objective literature reviews to demonstrate scientific validity. This includes reviewing peer-reviewed scientific literature, consensus opinions, clinical guidelines, and, when necessary, performing proof-of-concept studies.

Traceability: It is essential that the sources used in the scientific validity demonstration are traceable. This traceability ensures that the scientific evidence is credible and supports the association between the analyte and the intended medical purpose.

Methods and Approach: The methodology used in gathering and appraising scientific data should be documented in the performance evaluation plan (PEP). This includes specifying the methods for selecting, appraising, and analyzing relevant data, which may be sourced from various scientific databases and expert opinions.

State of the Art: Manufacturers must ensure that the scientific validity is consistent with the latest advancements in the field. This involves identifying relevant standards, consensus documents, and the scientific community’s general understanding of the analyte’s clinical relevance.

Performance evaluation : involves demonstrating scientific validity as part of a comprehensive assessment that also includes analytical and clinical performance of IVD devices. scientific validity confirms the theoretical underpinnings of the device, while analytical performance ensures it reliably measures the analyte and clinical performance confirms its utility in clinical practice.

Continuous Updates: scientific validity documentation should not be static. As new evidence emerges, manufacturers must update their performance evaluation reports, ensuring that the scientific validity of their device remains aligned with the most current research and clinical practices

The Regulatory Landscape: EU IVDR and Its Evolution

The EU IVDR, which came into force in 2017 and became applicable in May 2022, introduced much stricter requirements for IVD manufacturers compared to its predecessor, the IVD Directive (IVDD). These changes include a more comprehensive classification system, greater oversight by notified bodies, and enhanced post-market surveillance. The regulation requires that all CE-marked IVDs demonstrate compliance with safety, performance, and scientific validity standards. Health institutions using “in-house” devices must adhere to basic safety and performance standards, though they are not required to undergo full regulatory assessment if they are not marketed commercially. The IVDR has introduced the need for more detailed documentation, specifically requiring that manufacturers provide a thorough assessment of the scientific validity of their products, ensuring that they are not only reliable in their performance but also scientifically grounded.

Core Requirements for Demonstrating scientific validity (SV)

Scientific validity must be demonstrated for every IVD devices. The manufacturer needs to document:

The current state of scientific knowledge regarding the biomarker and its relationship to the medical condition.
Systematic literature review of peer-reviewed studies, meta-analyses, and clinical practice guidelines.
Traceability of sources and robust appraisal of the quality and relevance of all literature used.
Clearly stated methodology, including literature selection and appraisal process.
Comprehensive conclusion regarding the strength of the association with justification if data are limited or contested
The general safety and performance requirements listed in Sections 1 to 9 of Annex I must be supported by valid scientific evidence, as well as data on analytical and clinical performance.

Performance Evaluation Under IVDR

The performance assessment for IVDs involves three key elements:

scientific validity,
analytical performance, and
clinical performance.

Scientific validity demonstrates that the biomarker is scientifically relevant to the medical condition or physiological state. Analytical performance ensures that the device can reliably detect and measure the analyte of interest, while clinical performance correlates the device’s results with clinical outcomes, confirming its real-world applicability. These components together form the backbone of the device’s performance evaluation, and all must be documented and updated continuously in the device’s technical documentation. This process, outlined in Annexes I and XIII of the IVDR, ensures that the IVD device is not only scientifically valid but also reliable and effective in a clinical setting.

Steps for Manufacturers to Comply with Scientific Validity Requirements

Set up a rigorous performance evaluation process, integrating scientific validity appraisal as outlined in IVDR Annex XIII.
Conduct regular literature reviews, update evidence, and document all procedures and findings.
Develop systems for clinical evaluation if gaps in literature exist, such as proof-of-concept and clinical performance studies.

Note: In the case of interventional clinical performance studies, the analytical performance and scientific validity has been demonstrated, taking into consideration the state of the art. In cases where the scientific validity for companion diagnostics is not established, the scientific justification for using the biomarker must be provided.

Official Guidance and Resources

For scientific validity under the IVDR, manufacturers should refer to official guidance such as the Medical Device Coordination Group (MDCG) documents, particularly MDCG 2020-16, which provides clarification on classification and IVDR compliance. Manufacturers should also consult Annex XIII of the IVDR, which details performance evaluation processes, including scientific validity. In addition, regulatory bodies and consultancy firms provide resources and guidelines to navigate the scientific validity and performance evaluation processes under the IVDR. It is important to regularly refer to the European Medicines Agency (EMA) regulatory updates and peer-reviewed articles to stay informed about the latest regulatory changes and best practices.

Comparative Study: EU IVDR vs. Other Global IVD Regulations

To better understand how the EU IVDR stands in comparison to other global regulations for IVDs, here’s a table highlighting the key differences:

Aspect	EU IVDR 2017/746	US FDA (510(k) / PMA)	Japan (PMDA)	Canada (Health Canada)	India (CDSCO)
Risk Classification System	Four-class system (A, B, C, D)	Risk-based, no official classification scheme	Risk-based, similar to US and EU systems	Similar to EU’s classification system	Risk-based, aligned with global norms
Scientific Validity Requirement	Must demonstrate association of analyte with clinical condition	Required for new tests but less structured	Similar to EU, requiring validation studies	Similar to EU, requires evidence for clinical validity	Mandatory for all IVDs, documented evidence required
Performance Evaluation	Must document scientific validity, analytical and clinical performance	Focuses on analytical performance; clinical performance required in some cases	Emphasizes clinical and analytical performance	Requires both analytical and clinical performance validation	Requires scientific validity and performance data

Risk Classification and Scientific Validity

Under the EU IVDR, the required level of evidence for demonstrating scientific validity varies depending on the risk classification of the device. The risk-based classification system under IVDR divides IVD devices into four categories: Class A, B, C, and D, with Class A representing the lowest risk and Class D representing the highest.

Class A: For low-risk devices, manufacturers must demonstrate scientific validity through a thorough literature review and provide sufficient evidence to support the biomarker’s relevance to the intended medical purpose. The evidence may be less extensive compared to higher-risk devices, but it still needs to be robust and traceable.
Class B: These devices are considered moderate-risk, and the evidence for scientific validity must be more comprehensive. This often includes a systematic literature review and potentially additional studies or clinical data to substantiate the relationship between the analyte and the medical condition.
Class C: For high-risk devices, scientific validity must be demonstrated with a high level of scientific evidence. This typically includes extensive clinical data, peer-reviewed studies, and meta-analyses. Manufacturers may also be required to provide clinical performance studies and more detailed documentation.

Class D: For the highest-risk devices, the requirements for demonstrating scientific validity are the most stringent. Manufacturers must provide the most robust scientific evidence, including extensive clinical validation, peer-reviewed literature, and real-world performance data. These devices undergo the most rigorous scrutiny and require extensive technical documentation.

Scientific Validity Requirements for Class A In Vitro Diagnostic Devices under Rule 5(b) of the IVDR

Class A devices, as defined under Rule 5 of the In Vitro Diagnostic Regulation (IVDR), include a variety of products intended for general laboratory use and specific in vitro diagnostic procedures. Rule 5(b) outlines that instruments specifically designed by the manufacturer for use in such diagnostic procedures fall under the Class A category.

Scientific validity for these devices is significant to ensure that they perform their intended function reliably, especially when used in the diagnostic context. For devices falling under Rule 5(b), scientific validity refers to demonstrating that the device meets certain criteria to ensure accurate and reproducible results. This applies not only to the design and intended use of the devices but also to their ability to support clinical or laboratory diagnoses as specified by the manufacturer.

While Rule 5 outlines the basic classification, the scientific validity of these devices must also be established through robust evidence that aligns with the IVDR’s requirements for safety, performance, and traceability. Manufacturers of Class A devices must maintain documentation that proves the instrument’s performance is suitable for its intended in vitro diagnostic procedures, even if the device itself is relatively low-risk.

Identification of Relevant Software Models and Establishing Scientific Validity for IVD MDSW

When considering Medical Device Software (MDSW) in the context of In Vitro Diagnostic Medical Devices (IVDs), manufacturers need to ensure that their software is appropriately classified and evaluated for scientific validity. This is critical to demonstrate conformity with the General Safety and Performance Requirements (GSPRs) under the IVDR (EU 2017/746). There are several software models based on their intended purpose:

Independent MDSW with Clinical Benefit: Software intended for medical purposes that provides direct clinical benefit, requiring extensive clinical and performance evaluation (e.g., software that detects diseases or assists with diagnosis).

Software Driving or Influencing Another Medical Device: Software that supports or controls a medical device without a direct clinical benefit (e.g., software controlling insulin pumps). In such cases, clinical performance is assessed in conjunction with the device it supports.

Scientific Validity for IVD MDSW

To establish scientific validity for IVD MDSW, manufacturers must verify that the software’s outputs—based on its inputs and algorithms—are scientifically sound and aligned with the clinical conditions or physiological states defined by its intended purpose. This valid clinical association is supported through:

Literature reviews,
Clinical performance studies,
Data from curated databases or registries, and
Manufacturer’s own clinical investigations

Scientific Validity Requirements for Calibrators and Control Materials in IVDs

Scientific validity for calibrators and control materials in In Vitro Diagnostics ( IVDs) is crucial to ensure the accuracy and reliability of test results. According to the IVDR, scientific validity refers to the link between an analyte and a clinical condition or physiological state. For calibrators and control materials, scientific validity must be demonstrated by establishing that the analytes they contain are accurately linked to specific clinical conditions. This validation process may involve using existing data from peer-reviewed literature, clinical studies, or historical data. In cases where such data is insufficient or the device is novel, additional evidence, such as performance studies, may be required. The continuous evaluation of scientific validity is integral to maintaining compliance with the IVDR, ensuring that IVDs, including calibrators and control materials, consistently perform as intended throughout their lifecycle.

The Impact of IVDR Enforcement

The enforcement of the IVDR requires manufacturers to provide up-to-date, scientifically valid evidence as part of their conformity assessment and technical documentation. This means that during the IVDR submission process, manufacturers must not only update their technical files but also ensure that the scientific validity of their data is robust and aligned with the latest scientific standards. This includes a thorough review of biomarkers and other scientific evidence, which may lead to delays as manufacturers work to meet these stringent requirements. As a result, the IVDR submission process will demand a higher level of scientific rigor, setting a precedent for global regulatory practices in the field of IVDs.